Cargando…

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential

Background: Clinical management of ischemic events and prevention of vascular disease is based on antiplatelet drugs. Given the relevance of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) as a candidate target in thrombosis, the main goal of the present study was to identify novel antiplatele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barrachina, María N., Izquierdo, Irene, Hermida-Nogueira, Lidia, Morán, Luis A., Pérez, Amparo, Arroyo, Ana B., García-Barberá, Nuria, González-Conejero, Rocío, Troitiño, Sara, Eble, Johannes A., Rivera, José, Martínez, Constantino, Loza, María I., Domínguez, Eduardo, García, Ángel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037016/ https://www.ncbi.nlm.nih.gov/pubmed/33804911 http://dx.doi.org/10.3390/ijms22073304

Ejemplares similares

Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
por: Somoza, John R., et al.
Publicado: (2015)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha
por: Salloum-Asfar, Salam, et al.
Publicado: (2016)

miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis
por: del Monte, Alberto, et al.
Publicado: (2018)

Platelet Lipidome Fingerprint: New Assistance to Characterize Platelet Dysfunction in Obesity
por: Chicanne, Gaëtan, et al.
Publicado: (2022)

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
por: Adam, Etai, et al.
Publicado: (2017)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

Regulation of Coagulation Factor XI Expression by MicroRNAs in the Human Liver
por: Salloum-Asfar, Salam, et al.
Publicado: (2014)

Deciphering the secretome of leukocyte-platelet rich fibrin: towards a better understanding of its wound healing properties
por: Hermida-Nogueira, Lidia, et al.
Publicado: (2020)

Katacine Is a New Ligand of CLEC-2 that Acts as a Platelet Agonist
por: Morán, Luis A., et al.
Publicado: (2022)

An unusual case of Idelalisib‐related pneumonitis with severe respiratory failure
por: Sousa, Domingos, et al.
Publicado: (2020)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Control of post-translational modifications in antithrombin during murine post-natal development by miR-200a
por: Teruel, Raúl, et al.
Publicado: (2013)

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses
por: Alflen, Astrid, et al.
Publicado: (2018)

Rapid and complete response to idelalisib in a case of Richter syndrome
por: Bagacean, Cristina, et al.
Publicado: (2019)

Idelalisib induces PUMA-dependent apoptosis in colon cancer cells
por: Yang, Shida, et al.
Publicado: (2016)

Idelalisib may have the potential to increase radiotherapy side effects
por: Gryc, Thomas, et al.
Publicado: (2017)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
por: Kost, Sara E. F., et al.
Publicado: (2019)

A novel strategy for the manufacture of idelalisib: controlling the formation of an enantiomer
por: Mekala, Nagaraju, et al.
Publicado: (2018)

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K(δ) inhibitor idelalisib
por: Sandova, Veronika, et al.
Publicado: (2021)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis
por: Arroyo, Ana B., et al.
Publicado: (2020)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Regulation of TFPIα expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens
por: B. Arroyo, Ana, et al.
Publicado: (2017)

Management of adverse events associated with idelalisib treatment: expert panel opinion
por: Coutré, Steven E., et al.
Publicado: (2015)

Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice
por: Driscoll, Nancy
Publicado: (2016)

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
por: de Weerdt, Iris, et al.
Publicado: (2017)

Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma
por: Hengeveld, Paul J, et al.
Publicado: (2020)

Analysis of platelets from a diet-induced obesity rat model: elucidating platelet dysfunction in obesity
por: Barrachina, María N., et al.
Publicado: (2020)

GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: Elucidating potential anti-atherothrombotic targets in obesity
por: Barrachina, María N., et al.
Publicado: (2019)

Data on hyper-activation of GPVI signalling in obese patients: Towards the identification of novel antiplatelet targets in obesity
por: Barrachina, María N., et al.
Publicado: (2019)

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo
por: Palazzo, Adam, et al.
Publicado: (2018)

Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
por: Maffei, Rossana, et al.
Publicado: (2015)

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
por: Casadei, Beatrice, et al.
Publicado: (2022)

Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated α(IIb)β(3) Antagonist, Disintegrin
por: Kuo, Yu-Ju, et al.
Publicado: (2020)

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
por: Barrientos, Jacqueline C
Publicado: (2016)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease
por: Uday, R. V. Sriram, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gsq9kjc3c90tnrc3gvm9hcnm46